Inclusion Criteria:

A subject will be eligible for inclusion in this study only if all of
the following criteria apply:

1. Must be male ≥35 and ≤90 years of age

2. Have biopsy proven, localized prostate cancer

3. Gleason score ≤ 8

4. Clinical stage T1c-T2b

5. Serum PSA ≤10ng/mL within the 12 months period prior to positive prostate biopsy.

6. Able to swallow and retain oral medication

7. Able and willing to participate in the full duration of the study

8. Able to read and write (health outcomes questionnaires are self-administered),
understand instructions related to study procedures and give written informed
consent.

Exclusion Criteria:

1. Subject has ever been treated for prostate cancer with any of the following:

- Radiotherapy (external beam or brachytherapy)

- Chemotherapy

- Hormonal therapy (e.g., megestrol, medroxyprogesterone, cyproterone,
diethyl-stilbestrol (DES)

- Oral glucocorticoids

- Gonadotropin Releasing Hormone (GnRH) analogues (e.g., leuprolide, goserelin)
other than the single-dose gosereline given as treatment in this study.

2. Glucocorticoids, except inhaled or topical, are not permitted within 3 months prior
to visit one

3. Current and/or previous use of the following medications:

- Finasteride (Proscar, Propecia), or Dutasteride (Avodart) exposure within 6
months prior to study entry are excluded.

- Any other investigational 5-reductase inhibitors within the past 12 months.

- Anabolic steroids (subject must discontinued for 6 months prior to study entry
to be eligible)

- Drugs with antiandrogenic properties within the past 6 months (e.g,.
spironolactone, flutamide, bicalutamide, *cimetidine, *ketoconazole,
progestational agents) *The use of cimetidine is permitted prior to study entry.
The use of topical ketoconazole is permitted prior to and during the study.